FDA Approves New First-Line Med for Pancreatic Cancer as Drug’s Initial Developer Dissolves

MedCity News February 14, 2024
Frank Vinluan

Ipsen’s Onivyde is now FDA approved as a first-line treatment for metastatic pancreatic cancer, triggering a milestone payment to Merrimack Pharmaceuticals, the drug’s original developer. Merrimack plans to dissolve operations but its shareholders will receive payouts from the Ipsen payment.

Pancreatic cancer continues to be one of the most difficult-to-treat cancers. An Ipsen drug is now approved as a first-line therapy, moving it up in the treatment hierarchy for this type of cancer.

The drug, Onivyde, was initially approved as a second-line therapy for pancreatic cancer in adults whose disease has advanced following treatment with standard chemotherapies. In expanding to first-line treatment of metastatic disease, the drug must continue to be used in combination with chemotherapy, according to the FDA...

Today's Sponsors

Today's Sponsor